Forbion
Finance · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Gooimeer 2-35, Naarden, North Holland, 1...Phone Number
+31 356993000Website
www.forbion.comRevenue
$24.1 MillionIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
2
1
2
1
2
About Forbion
Forbion is a global life sciences venture capital firm headquartered in Naarden, the Netherlands, with additional offices in Munich, Germany, and Boston, USA. Originally established in 2000 as ABN AMRO Capital Life Sciences, the firm spun out as an independent entity in 2006 and has since built a strong track record of sourcing, building, and guiding biotech and biopharmaceutical companies from early stage through clinical development. Forbion invests across multiple fund strategies covering all stages of pharmaceutical drug development, with a primary focus on innovative therapeutics companies in Europe and North America. Beyond human health, the firm extends its biotechnology expertise through its BioEconomy fund strategy, which invests in companies developing sustainable solutions across food, agriculture, materials, and environmental technologies. Forbion operates a joint venture with BioGeneration Ventures for seed and early-stage investments, and is a signatory to the United NatiRead more
Forbion Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Forbion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Forbion had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Forbion has new funding data
Website visits: Recent activity has been detected on your website
Check if Forbion has recently received funding, and reach out quickly before it becomes old news!
Check out if Forbion is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Forbion
Earning: See what the market has to say on Forbion recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Forbion launches new products
Forbion, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Forbion as Masked Content
Find 3 more new buyers
Compare Similar Companies to Forbion
Compare insights from companies similar to Forbion, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Forbion is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Forbion is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Forbion.
Forbion financials insights
Gather financial insights about Forbion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Unspecified
$2.2B
Forbion Tech Stack
A closer look at the technologies used by Forbion
Most Recent Scoops
Person-Based
Board of Directors, Mergers
Project
Spending/Investment
Person-Based
Events, Pharmaceuticals
Person-Based
Funding, Finance
Person-Based
Finance, Financing & Debt, Regulations
Forbion News & Media
Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- Memento Medicines, Inc., a privately-held biotech company developing biologic therapies for retinal diseases, today announced the completion of a $93M Series A financing round co-led by Forbion, RA Capital Management and Avego BioScience Capital, with participation from Sanofi Ventures and Samsara BioCapital. In connection with the financing, Memento also announced that it has entered into an exclusive license agreement with MabTics Co., Ltd. and CuracleForbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner
Forbion announces the promotions of Jon Edwards, PhD, to General Partner, Regina Salvat, PhD, to Partner, and John McDonald, MBA, as Operating Partner.Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. (NASDAQ: RAPT) in a transaction valued at $2.2 billion.Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic
Gate Bioscience closes $65M Series B to advance molecular gates, oral drugs that eliminate disease proteins, into clinical trials for CNS/inflammation
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Forbion
Sign Up For FreeTo access detailed company insights
Forbion is a global life sciences venture capital firm headquartered in Naarden, the Netherlands, with additional offices in Munich, Germany, and Boston, USA. Originally established in 2000 as ABN AMRO Capital Life Sciences, the firm spun out as an independent entity in 2006 and has since built a strong track record of sourcing, building, and guidi... Read More
